2 for Obesity

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Obesity+1 More
Estrogen cream - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to determine if estrogen or testosterone can affect cortisol levels and where fat builds up in our bodies.

Eligible Conditions
  • Menopausal Syndromes
  • Obesity

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Obesity

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Before and after hormone replacement therapy

Before and after hormone replacement therapy
To measure 24-hour CPR, free cortisol, and cortisol binding globulin levels in plasma; HSD 1 activity, glucocorticoid receptor binding, and cortisol levels in adipocytes; and urinary excretion of cortisol, cortisone and their metabolites.
To measure intramyocellular fat and intrahepatic fat by MRS, visceral and subcutaneous abdominal fat by CT scan, body composition (fat mass, lean mass, and bone mass) by DXA, and insulin sensitivity.

Trial Safety

Safety Progress

1 of 3

Other trials for Obesity

Trial Design

5 Treatment Groups

2
1 of 5
3
1 of 5
5
1 of 5
1
1 of 5
4
1 of 5
Active Control
Non-Treatment Group

140 Total Participants · 5 Treatment Groups

Primary Treatment: 2 · Has Placebo Group · N/A

2
Drug
ActiveComparator Group · 1 Intervention: Depo Lupron/Aromatase inhibitor · Intervention Types: Drug
1
Drug
PlaceboComparator Group · 1 Intervention: Placebo injection · Intervention Types: Drug
3
Drug
ActiveComparator Group · 1 Intervention: Depo Lupron/placebo · Intervention Types: Drug
4
Drug
PlaceboComparator Group · 1 Intervention: placebo · Intervention Types: Drug
5
Drug
ActiveComparator Group · 1 Intervention: Estrogen cream · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: before and after hormone replacement therapy

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
885 Previous Clinical Trials
6,828,454 Total Patients Enrolled
27 Trials studying Obesity
8,847 Patients Enrolled for Obesity
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,117 Previous Clinical Trials
5,053,754 Total Patients Enrolled
394 Trials studying Obesity
1,479,269 Patients Enrolled for Obesity
Jonathan Q. Purnell, M.D.Principal InvestigatorOHSU - Center for the Study of Weight Regulation
4 Previous Clinical Trials
123 Total Patients Enrolled
4 Trials studying Obesity
123 Patients Enrolled for Obesity

Eligibility Criteria

Age 18 - 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: October 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.